These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10971267)

  • 21. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.
    Elhilali M; Emberton M; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Alcaraz A; Vallancien G;
    BJU Int; 2006 Mar; 97(3):513-9. PubMed ID: 16469018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Impact of alfuzosin 10 mg once daily on quality of life in Tunisian patients with lower urinary symptoms suggestive of benign prostatic hyperplasia].
    Ben Rhouma S; H'sairi M; Adbi H; Binous MY; Nouira Y; Ben Raies N; Mosbah AT; Horchani A
    Tunis Med; 2015 Mar; 93(3):164-9. PubMed ID: 26367405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
    Wilde MI; Fitton A; McTavish D
    Drugs; 1993 Mar; 45(3):410-29. PubMed ID: 7682910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical uroselectivity: a 3-year follow-up in general practice. BPH Group in General Practice.
    Lukacs B; Grange JC; McCarthy C; Comet D
    Eur Urol; 1998; 33 Suppl 2():28-33. PubMed ID: 9556193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study.
    van Kerrebroec P; Jardin A; van Cangh P; Laval KU;
    Eur Urol; 2002 Jan; 41(1):54-60; discussion 60-1. PubMed ID: 11999466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
    Kaplan SA; Gonzalez RR; Te AE
    Eur Urol; 2007 Jun; 51(6):1717-23. PubMed ID: 17258855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
    Emberton M; Elhilali M; Matzkin H; Harving N; van Moorselaar J; Hartung R; Alcaraz A; Vallancien G;
    Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group.
    Buzelin JM; Roth S; Geffriaud-Ricouard C; Delauche-Cavallier MC
    Eur Urol; 1997; 31(2):190-8. PubMed ID: 9076465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
    Lukacs B; Leplège A; Thibault P; Jardin A
    Urology; 1996 Nov; 48(5):731-40. PubMed ID: 8911517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin.
    McNeill SA; Hargreave TB; Geffriaud-Ricouard C; Santoni J; Roehrborn CG
    Urology; 2001 Mar; 57(3):459-65. PubMed ID: 11248620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
    Fourcade RO
    Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
    Roehrborn CG; Van Kerrebroeck P; Nordling J
    BJU Int; 2003 Aug; 92(3):257-61. PubMed ID: 12887479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group.
    Buzelin JM; Hebert M; Blondin P
    Br J Urol; 1993 Dec; 72(6):922-7. PubMed ID: 7508331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
    Lowe FC
    Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia.
    Hwang TI; Chu SH; Lin MS; Chen CS; Lee LM; Chang HC; Yeh SD; Chen WH; Chiang PH
    Kaohsiung J Med Sci; 2012 Aug; 28(8):429-34. PubMed ID: 22892164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin.
    Saad F; Nickel JC; Valiquette L; Casey R; Kuzmarov I; Elhilali M;
    Can J Urol; 2005 Aug; 12(4):2745-54. PubMed ID: 16197598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, efficacy and impact on Patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH. The Italian Alfuzosin Co-Operative Group.
    Eur Urol; 2000 Jun; 37(6):680-6. PubMed ID: 10828668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms.
    Kaplan SA; Reis RB; Cologna A; Suaid HJ; Martins AC; Kohn IJ; Te AE
    Urology; 1998 Jul; 52(1):12-6. PubMed ID: 9671862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study)].
    Pushkar DY; Loran OB; Bernikov AN
    Urologiia; 2022 Dec; (6):21-29. PubMed ID: 36625609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.